Skip to main content
. 2012 May;5(1):31–38. doi: 10.15283/ijsc.2012.5.1.31

Table 3.

Concentration of cytokine and chemokine (pre-and post-) in serum from CP patients with either allogenic (n=3) or autologous (n=4)

Allogeneic (N=3) Autologous (N=4) p-value

Pre (pg/ml) Post 24 h (pg/ml) Difference Pre (pg/ml) Post 24 h (pg/ml) Difference

IL-1aa 29.69±33.86 24.94±28.38 -4.75±5.54 147.15±189.88 155.3±204.22 8.14±16.02 0.04
IL-6a 23.81±3.94 8.89±10.29 -14.92±9.07 59.53±77.27 60.13±80.01 0.61±4.52 0.04
IL-15a 10.72±2.4 12.73±2.29 2.01±0.5 107.42±140.18 104.41±139.6 -3.01±4.02 0.05
CCL5/RANTESa 4,423.95±482.08 3,051.15±490.01 -1,372.8±353.97 2,796.13±324.69 2,901.74±398.66 105.61±118.86 0.05
TNFβa 23.72±14.89 18.45±14.87 -5.27±1.11 200.84±280.02 201.35±282.64 0.51±3.06 0.05
CCL4/MIP-1β 307.38±367.2 60.39±37.18 -246.99±336.28 137.11±107.92 158.2±148.77 21.1±43.53 0.11
IL-5 0.31±0.54 0.11±0.18 -0.21±0.36 16.15±28.83 16.35±28.97 0.2±0.23 0.17
CCL3/MIP-1α 1,009.85±1,286.47 58.93±54.68 -950.92±1,237.62 55.4±106.51 54.06±108.13 -1.34±3.49 0.19
sCD40L 9,900.8±171.81 10,000±0 -99.2±171.81 8,637.55±954.67 9,722.46±555.07 1,084.92±891.66 0.19
IL-8/CXCL8 421.77±531.57 24.32±5.25 -397.46±533.18 60.26±69.99 55.27±63.42 -4.99±6.91 0.21
IFNr 31.86±36.83 8.91±2.88 -22.95±34.5 163.65±281.49 169.24±305.21 5.59±26.15 0.21
sIL-2Rα 167.84±33.57 165.66±31.5 -2.18±21.03 349.96±166.82 421.88±185.4 71.92±66.69 0.21
Flt-3 Ligand 58.54±34.3 27.95±4.75 -30.59±32.8 139.97±186.59 143.61±185.08 3.64±8.73 0.21
GM-CSF 81.24±105.54 27.72±41.14 -53.52±65.44 179.95±341.54 162.61±305.93 -17.33±35.69 0.21
IL-2 4.17±2.23 2.94±0.9 -1.23±1.47 36.45±61.67 38.37±66.74 1.92±5.24 0.21
IL-13 11.29±10.12 9.14±9.51 -2.16±1.26 73.39±111.49 72.48±108.48 -0.91±3.59 0.37
EGF 65.81±56.2 42.08±33.1 -23.73±29.85 21.71±38.36 33.15±28.68 11.44±38.17 0.37
VEGF 218.84±175.58 73.41±5.29 -145.42±172.97 437.95±769.7 412.26±673.76 -25.69±100.2 0.37
IL-17 4.37±5.61 0.41±0.72 -3.96±4.92 84.45±158.13 79.84±143.8 -4.61±15.1 0.52
IL-1b 8.62±14.92 0±0 -8.62±14.92 72.58±117.46 73.58±119.79 1±2.43 0.55
IL-9 0±0 0±0 0±0 5.48±10.96 4.77±9.54 -0.71±1.42 0.56
IFNa2 0±0 0±0 0±0 166.31±332.63 171.05±342.1 4.74±9.48 0.56
G-CSF 0±0 0±0 0±0 41.26±82.52 46.05±92.1 4.79±9.58 0.56
PDGF-AB/BB 10,000±0 10,000±0 0±0 10,000±0 9,187.66±1,624.68 -812.34±1,624.68 0.56
IL-4 5.57±9.01 2.09±3.63 3.48±5.39 88.46±151.91 92.01±141.74 3.55±19.07 0.58
IL-10 34.66±4.47 34.07±17.48 0.59±14.29 158.22±235.78 157.5±237.87 -0.72±2.18 0.59
IL-12(p40) 55.31±27.9 41.55±15.89 13.76±17 243.22±321.25 277.6±401.88 34.38±82.3 0.59
CCL7/MCP-3 87.21±45.21 83.13±45.43 4.09±3.01 253.1±324.63 244.48±319.72 -8.62±12.56 0.59
TNFα 22.31±19.58 7.79±3.11 14.52±16.74 18.72±25.2 17.66±26.11 -1.06±0.94 0.59
CCL2/MCP-1 468.39±75.59 437.75±51.21 30.64±126.3 890.61±495.35 819.58±523.94 -71.03±146.34 0.85
CCL11/Eotaxin 78.93±26.87 77.01±39.15 1.92±12.86 101.47±103.04 103±87.51 1.53±23.89 0.85
CCL22/MDC 2,545.56±310.98 2,176.97±368.79 368.59±239.21 2,762.14±511.62 2,362.79±408.48 -399.35±312.24 0.85
CX3CL1 126.5±91.12 116.07±67.11 10.44±35.54 714.94±918.12 704.45±968.69 -10.49±55.24 0.85
/Fractalkine
TGFα 19.97±7.22 18.35±4.25 1.62±3.55 72.55±114.19 71.61±107.82 -0.94±8.42 0.85
IL-1ra 100.6±72.77 71.25±13.83 29.35±59.65 329.54±460.32 324.54±441.13 -5±20.85 1
IL-3 0±0 0±0 0±0 0±0 0±0 0±0 1
IL-7 0±0 0±0 0±0 30.82±59.53 30.67±58.2 0.15±1.55 1
IL-12(p70) 7.14±2.13 -5.74±1.26 -1.4±2.65 80±143.97 74.42±132.48 5.58±11.53 1
CXCL1/GROα 792.65±333 -814.92±302.73 22.27±54.61 896.52±358.54 955.57±287.98 -59.05±114.21 1
CXCL10/IP-10 237.07±27.65 -212.79±55.96 24.27±74.31 270.85±79.38 230.76±73.59 40.09±42.78 1
FGF-2 123.82±76.46 -75.53±17.69 48.29±59.32 406.61±634.33 376.09±614.75 30.51±28.35 1
PDGF-AA 7,682.55±1493.7 8,020.52±487.87 337.97±1,124.51 6,461.26±2,424.62 6,645.9±2,984.82 184.64±1,116.36 1